Europe Dermal Fillers Market size exceeded USD 1.2 billion in 2021 and is anticipated to exhibit a CAGR of 9.5% from 2022 to 2028. Expanding population base of elderly in the region will accelerate the market revenue.

Get more details on this report - Request Free Sample PDF

Dermal fillers are also called as injectable implants or soft tissue fillers that are used to enhance appearance of the face. This material is designed to be injected into the skin to add volume and fullness. They produce a smoother and fuller appearance in the chin, lips and face and are being rapidly adopted since past few years. Dermal filler treatment for skin rejuvenation is a non-invasive alternative to surgical procedures that refills skin volume, clears wrinkles, and enhances facial aesthetics. Growing emphasis on aesthetics across developed countries has stimulated the market growth.

Europe Market, By Type

The biodegradable segment revenue in the Europe dermal fillers market was over USD 1 billion in 2021. Biodegradable filler materials such as hyaluronic acid and calcium hydroxyapatite (CaHA) are safe and lasts up to limited period allowing consumer to switch back to their original look. This factor majorly drives the consumer preference. Moreover, enhanced biocompatibility of these compounds further accelerates its adoption rate among consumer population.

Europe Market, By Material Type

The hyaluronic acid segment dominated over 90% Europe dermal fillers market share in 2021, owing to wide-spread acceptance and high usage of HA fillers in the region. These fillers are used across broad range of applications and is a naturally occurring substance in the body, thus rarely produce any adverse effect on application. Moreover, HA fillers are mostly used for deeper lines and wrinkle treatment and offer long-term sustainability owing to thicker consistency.

Europe Dermal Fillers Market, By Application

The facial line correction segment will showcase 10.2% growth rate during the forecast timeline, owing to rising demand among elderly population to diminish signs of aging coupled with increasing awareness and consciousness regarding facial aesthetics. In addition, increasing popularity of non-invasive aesthetic procedures stimulates its preference among the female population.

Europe Market, By End-use

The dermatology clinics segment accounted for 50% Europe dermal fillers market share in 2021. Expanding number of such facilities coupled with integration of advanced technologies will accelerate the patient preference towards such type of settings. Additionally, these clinics provide consultation and customized services to their clients will accelerate the market size. Growing sophisticated healthcare infrastructure along with presence of skilled plastic surgeons across European countries will influence the market revenue.

Europe Market, By Country

Italy dermal fillers market was valued at USD 200 million in 2021, attributed to high awareness and adoption of cosmetic treatments along with considerable spending on aesthetics. Moreover, rapid adoption of non-invasive procedures is estimated to boost the market size. Strong presence of numerous market players focusing on novel product development will fuel the market share. Additionally, well-developed infrastructure and presence of expertise in the country will further stimulate the demand for dermal fillers in Italy.

Competitive Industry Landscape

Some of the leading companies involved in the market include AbbVie, Inc., Merz Pharma, Galderma S.A., Anika Therapeutics Inc., Chroma Pharma GmbH, Cytophil Inc., Huons Global Co., Ltd., Prollenium Medical Technologies, Shanghai Bioha Technology, Co., Ltd., Sinclair Pharma, Suneva Medical Inc., Teoxane Laboratories and Zhejiang Jingjia Medical Technology Co., Ltd.

These companies are pursuing several growth strategies such as mergers and acquisitions, product launches, and distribution partnerships to maintain their market position. For instance, in March 2022, Allergan Aesthetics part of AbbVie launched HArmonyCa with Lidocaine, a dual-effect hybrid injectable containing hyaluronic acid and calcium hydroxylapatite for better aesthetic outcome. This strategic move strengthened the company’s product portfolio as well as position in the industry.